Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The therapeutic treatment of negative symptoms and cognitive dysfunction associated with schizophrenia is a significant unmet medical need. Preclinical literature indicates that α7 neuronal nicotinic acetylcholine (nACh) receptor agonists may provide an effective approach to treating cognitive dysfunction in schizophrenia. We report herein the discovery and evaluation of (BMS-933043), a novel and potent α7 nACh receptor partial agonist with high selectivity against other nicotinic acetylcholine receptor subtypes (>100-fold) and the 5-HT receptor (>300-fold). activity was demonstrated in a preclinical model of cognitive impairment, mouse novel object recognition. BMS-933043 has completed Phase I clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346989 | PMC |
| http://dx.doi.org/10.1021/acsmedchemlett.7b00032 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objectives: Azapirone-class drugs are partial 5-HT1A receptor agonists commonly used to treat anxiety disorders. Prior experimental studies have so far demonstrated that these drugs have low potential for dependence and problematic use and are considered safe treatment options compared with benzodiazepines. However, recent evidence suggesting the contrary raises concerns about their safety.
View Article and Find Full Text PDFBrexpiprazole in the Management of Schizophrenia: A Consensus Report of Best Practices From Acute to Maintenance Treatment.
Neuropsychiatr Dis Treat
August 2025
Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York, USA.
Brexpiprazole is a second-generation antipsychotic with multiple indications, including the treatment of schizophrenia. As a partial dopamine agonist, brexpiprazole differs from most other antipsychotics, yet uncertainties about its full mechanism of action have led to some ambiguity among prescribers. To address this gap, an international panel of psychiatric experts was organized and convened with funding from Otsuka Pharmaceutical Europe Ltd and H.
View Article and Find Full Text PDFDopamine DR availability after discontinuation of antipsychotic treatment: a [C]raclopride PET study in remitted first-episode psychosis patients.
Psychol Med
September 2025
https://ror.org/03cv38k47University of Groningen, University Medical Centre Groningen, Center for Clinical Neuroscience and Cognition, Groningen, The Netherlands.
Background: After remission of a first-episode psychosis (FEP), antipsychotic discontinuation is associated with an increased risk of relapse compared to maintenance treatment. We studied short and longer-term effects of discontinuation of D receptor (DR) antagonist and partial agonist antipsychotics on striatal dopamine DR availability in FEP patients.
Methods: Remitted FEP patients underwent two [C]raclopride PET scans to measure striatal DR availability: 1 week after antipsychotic discontinuation (n = 16 antagonist users, n = 6 partial agonist users) and after being medication free for 6-8 weeks (n = 8 antagonist users, n = 5 partial agonist users).
Effects of Naltrexone on Gabapentin Reward and Buprenorphine Combinations in Male Mice.
Behav Brain Res
September 2025
Department of Psychological Science, Northern Michigan University.
Gabapentin (GBP), an anticonvulsant approved for seizures and neuropathic pain, is frequently co-prescribed with buprenorphine (BUP), a partial mu-opioid receptor (MOR) agonist, to manage withdrawal and pain in individuals with opioid use disorder (OUD). While GBP is generally considered safe, emerging evidence suggests abuse potential when combined with opioids. This study used the conditioned place preference (CPP) paradigm to assess the rewarding effects of GBP alone and in combination with BUP.
View Article and Find Full Text PDFTriggering receptor expressed on myeloid cells 2 (TREM2) is a microglia-specific receptor whose activation promotes phagocytosis and neuroprotection in Alzheimer's disease (AD) and related neurodegenerative disorders. While therapeutic efforts have largely focused on antibodies, small molecule TREM2 modulators remain limited. Here, we applied a structure- based virtual screening workflow targeting a putative allosteric site on TREM2, guided by PyRod-derived pharmacophores from molecular dynamics simulations.
View Article and Find Full Text PDF